
Oncology NEWS International
- Oncology NEWS International Vol 11 No 8
- Volume 11
- Issue 8
Advectus Life Sciences Begins Preclinical Trials of P80DOX-NP
VANCOUVER, Canada-Ad-vectus Life Sciences Inc. has begun preclinical testing of its patented nanoparticle-based technology (Nanocure) at the University of North Carolina Brain Tumor Center. This series of studies will test the Nanocure
VANCOUVER, CanadaAd-vectus Life Sciences Inc. has begun preclinical testing of its patented nanoparticle-based technology (Nanocure) at the University of North Carolina Brain Tumor Center. This series of studies will test the Nanocure formulation P80DOX-NP on rodent brain metastases arising from lung, breast, renal cell, and colon cancers, and melanoma, the company announced.
P80DOX-NP is a novel method for the delivery of doxorubicin across the blood-brain barrier. The randomized, placebo-controlled study will measure survival as a surrogate for intracranial tumor progression/regression.
Articles in this issue
almost 24 years ago
Medicaid Gives New Protections to Beneficiaries in Managed Care Plansalmost 24 years ago
Prostate Cancer Cell Line Vaccine Promising in Phase II Trialalmost 24 years ago
MoAb Targeting Death Receptor in Breast Canceralmost 24 years ago
Hanford I-131 Releases Did Not Increase Thyroid Cancer Riskalmost 24 years ago
Chemo/Rituximab Is Effective as First-Line CLL Therapyalmost 24 years ago
Diagnostic Dilemmaalmost 24 years ago
Viral Agent ONYX-015 Targets p53-Deficient Cancer Cellsalmost 24 years ago
Program Educates Teens About Testicular Cancer Self-Examalmost 24 years ago
Better Colon Cancer Imaging With PET/CT Than With PET Alonealmost 24 years ago
Delayed Lung Cancer Screening Trial to Begin Enrollment 50,000 SubjectsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.

















































